Most Read Articles
Elvira Manzano, 02 Oct 2018
Triple therapy with budesonide, glycopyrrolate, and formoterol in one metered dose inhaler (BGF MDI) appears effective and is well-tolerated in patients with symptomatic moderate-to-severe chronic obstructive pulmonary disease (COPD) irrespective of exacerbation history, the multicentre, phase III KRONOS* trial has shown.
Dr. Fanny Wai-San Ko, Dr. Wing-Ho Yip, 15 Aug 2018
Although a majority of patients can achieve good asthma control with the use of inhaled corticosteroid (ICS) and bronchodilators, some patients’ asthma remain uncontrolled despite the use of these medications.
Stephen Padilla, 14 Jan 2019
Overall, the risk of lung cancer is higher in former and current smokers with higher concentrations of high sensitivity C-reactive protein (hsCRP), according to a study. Additionally, circulating hsCRP is not associated with the risk of lung adenocarcinoma and may reflect a prediagnostic disease state rather than a causal risk for lung cancer.
20 Feb 2018
Dr Michael Lim, consultant of the Division of Paediatric Pulmonary and Sleep in National University Hospital, Singapore, shares his insights with Pearl Toh on diagnosing and managing paediatric asthma in the primary care setting.

Controversies in paediatric empyema management: Fibrinolytics or surgery?

Pearl Toh
06 Dec 2017
Dr Adam Jaffe

Chest drain with fibrinolytics is as good as video-assisted thoracoscopic surgery (VATS) in the management of childhood empyema, with fibrinolytics being a cheaper option than VATS, according to a presentation at the APSR 2017 Congress.

Being highlighted was a prospective randomized study which showed that the primary endpoint of length of hospital stay was similar following chest drain with intrapleural urokinase or VATS (median, 6 vs 6 days; p=0.311) among the 60 children enrolled. [Am J Respir Crit Care Med 2006;174:221-227]

There were also no significant differences in other secondary endpoints such as total hospital stay (median, 13 vs 14 days; p=0.65), treatment failure rate (five in each group), and days with chest drain (median, 5 vs 4 days; p=0.055). The mean treatment cost per patient in the VATS arm was £6,322 compared with £5,071 in the urokinase arm (p<0.05).

These findings were corroborated by another prospective randomized study which showed no therapeutic or recovery advantages with VATS vs fibrinolysis with tissue plasminogen activator (tPA) for treating empyema. [J Pediatr Surg 2009;44:106-111] Furthermore, using fibrinolytics as first-line treatment for paediatric empyema demonstrated that the mean length of hospital stay was 7.2 days, with no major side effects, [J Pediatr Surg 2013;48:1312-1315] indicating that real-life experience with fibrinolysis yields similar results to randomized controlled trials.

“The take-home message is that urokinase or tPA small chest drain is as good as VATS … and also cheaper,” said Professor Adam Jaffe from the School of Women’s and Children’s Health at University of New South Wales in Sydney, Australia.

With regards to risk factors predictive of treatment failure with fibrinolytics in children, a positive blood culture (odds ratio [OR], 2.7) and immediate admission to intensive care (OR, 2.1) have been associated with an increased risk of treatment failure. [J Pediatr Surg 2016;51:832-837] 

“There is no need for routine CT scan [before placement of drains],” added Jaffe, as the additional information obtained from a CT scan did not alter management and were not predictive of clinical outcome. [Thorax 2008;63:897-902] “The choice of radiological assessment is ultrasound, which is also safer in children.”

Nonetheless, pleural drainage is not always necessary, according to Jaffe, as some children with empyema can have reasonably short length of hospital stay with intravenous antibiotics alone. Among 182 children hospitalized with empyema, 52 percent who received antibiotics alone had a significantly shorter length of hospital stay than the 45 percent who subsequently underwent drainage procedures (mean, 7 vs 11 days). [Pediatr Pulmonol 2010;45:475-480]

The strongest predictors of requiring pleural drainage include admission to intensive care, a large effusion size filling up to more than half of the thorax, and younger age; while pleural fluid loculation is not a predictor. [Pediatr Pulmonol 2010;45:475-480]  

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 02 Oct 2018
Triple therapy with budesonide, glycopyrrolate, and formoterol in one metered dose inhaler (BGF MDI) appears effective and is well-tolerated in patients with symptomatic moderate-to-severe chronic obstructive pulmonary disease (COPD) irrespective of exacerbation history, the multicentre, phase III KRONOS* trial has shown.
Dr. Fanny Wai-San Ko, Dr. Wing-Ho Yip, 15 Aug 2018
Although a majority of patients can achieve good asthma control with the use of inhaled corticosteroid (ICS) and bronchodilators, some patients’ asthma remain uncontrolled despite the use of these medications.
Stephen Padilla, 14 Jan 2019
Overall, the risk of lung cancer is higher in former and current smokers with higher concentrations of high sensitivity C-reactive protein (hsCRP), according to a study. Additionally, circulating hsCRP is not associated with the risk of lung adenocarcinoma and may reflect a prediagnostic disease state rather than a causal risk for lung cancer.
20 Feb 2018
Dr Michael Lim, consultant of the Division of Paediatric Pulmonary and Sleep in National University Hospital, Singapore, shares his insights with Pearl Toh on diagnosing and managing paediatric asthma in the primary care setting.